Tuberculosis

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Administration, Nontuberculous mycobacteria, Conference, Bill, AN2, Entrepreneurship, NTM, Boron, Tuberculosis, University, Patient, Melioidosis, Data monitoring committee, G&A, MAC, Insurance, Infection, Wellcome Trust, Investment, Clinical trial, Chagas disease, Therapy, Malaria, Safety, Poster, Research and development, Mycobacteroides abscessus, IDSA, Trust, Pharmaceutical industry

Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.

Key Points: 
  • Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.
  • Net loss: Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year.
  • Net loss for the fourth quarter of 2023 was $16.9 million, compared to $11.8 million for the same period during 2022.
  • Cash Position: The Company had cash, cash equivalents, and investments of $134.5 million at December 31, 2023.

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

Ketolides Market Expects Robust Growth With Rising Infectious Disease Prevalence - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Infectious Diseases, Pharmaceutical, Health, Ketolide, Sinusitis, Pharmacy, Infection, Urinary tract infection, Hospital, Prevalence, Antimicrobial stewardship, Tuberculosis, Pharmaceutical industry

The global ketolides market is poised for steady expansion, driven by the growing need for effective treatments for infectious diseases and an upsurge in healthcare investments.

Key Points: 
  • The global ketolides market is poised for steady expansion, driven by the growing need for effective treatments for infectious diseases and an upsurge in healthcare investments.
  • According to the latest market research report, the ketolides market showcases a promising compound annual growth rate (CAGR), signaling a positive trajectory from $3.07 billion in 2023 to a projected value of $3.82 billion by 2028.
  • It also identifies emerging trends in targeted therapies and advancements in diagnostic procedures that are augmenting the ketolides market landscape.
  • The report underscores North America's dominance in the ketolides arena, attributable to robust healthcare infrastructure, comprehensive screening programs, and a heightened focus on infectious disease control.

Yes! We Can End TB & AIDS, Says AHF

Retrieved on: 
Friday, March 22, 2024
White House, Federal Government, Public Policy, Other Health, General Health, Women, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Men, LGBTQ+, Foundation, Other Philanthropy, AIDS, Consumer, Health, Coinfection, AIDS Healthcare Foundation, Tuberculosis, World Tuberculosis Day, HIV, Global health, Education, Death, Infection, World Health Organization, Multidrug-resistant tuberculosis, TB, MDR-TB, AHF, Multimedia, Pharmaceutical industry

We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.

Key Points: 
  • We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.
  • View the full release here: https://www.businesswire.com/news/home/20240322482439/en/
    AIDS Healthcare Foundation (AHF) country teams, which have prioritized screening for TB in clinics—along with preventing and treating HIV/TB co-infection—will hold World TB Day commemorations around the globe.
  • Integrating TB prevention and care into HIV programs, which AHF has done, is essential for comprehensive healthcare.
  • We Can End TB & AIDS.’”
    According to the World Health Organization, TB claimed 1.3 million lives in 2022, including 167,000 people living with HIV, with an estimated nearly 11 million people falling ill to TB worldwide.

Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment

Retrieved on: 
Thursday, March 21, 2024
Health, General Health, Conference, Worldwide, Bill, Commercialization, Medication, Disease, Tuberculosis, Fungal infection, COVID-19, Patient, QBS, Bacteria, Safety, TB, Ōtsuka, Pharmaceutical industry

Otsuka Pharmaceutical Development & Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd., announce that interim data from a Phase 2b/c trial exploring quabodepistat (QBS), in combination with delamanid and bedaquiline, for the treatment of pulmonary tuberculosis (TB) is positive and may shorten the duration of TB treatment for patients.

Key Points: 
  • Otsuka Pharmaceutical Development & Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd., announce that interim data from a Phase 2b/c trial exploring quabodepistat (QBS), in combination with delamanid and bedaquiline, for the treatment of pulmonary tuberculosis (TB) is positive and may shorten the duration of TB treatment for patients.
  • QBS is an investigational anti-tuberculosis compound which has a new mechanism of action that interferes with the cell-wall structure of the bacteria causing TB.1,2 Worldwide, TB is the second leading infectious fatal disease after COVID-19 .
  • The three-drug QBS-based arms were well-tolerated, with no serious treatment emergent adverse events reported, related to the regimens.3
    The ongoing study, supported by Otsuka and the Bill & Melinda Gates Foundation, is being held across six clinical research sites in South Africa.
  • Full results of this phase 2b/c, randomized trial are expected by the end of 2024.2,3

Global Respiratory Care Devices Market Report, 2023-2024 and 2030: Infrastructure Improvements Key to Growth, Innovations in AI to Transform the Market Landscape - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2024
Medical Devices, Hospitals, Health, Health Technology, Medical Supplies, Hospital, Sleep apnea, Prevalence, Pneumonia, Emphysema, Tuberculosis, Intelligence, Incidence, Ageing, Patient, Respiratory therapist, Tissue, Chronic obstructive pulmonary disease, Research, Record, Quality of life, Human, Respiratory disease, Asthma, World Health Organization, CDC, Oxygen, WHO, TB, RMT, COPD, Allergy, Respiration, USD, Agonal respiration, Personal protective equipment

The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.

Key Points: 
  • The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.
  • This drives the demand for respiratory care devices to maintain adequate respiration and ensure most advantageous respiratory characteristic.
  • As the number of humans identified with respiration illnesses will increase, the demand for respiratory care devices is predicted to grow.
  • The Global Respiratory care devices marketplace requires a dependable and efficient infrastructure for low-earning individuals or healthcare centers.

Canadian MedTech Startup Amplifies Fight Against Tuberculosis with New Grant

Retrieved on: 
Thursday, March 28, 2024
Diagnosis, TB, World Health Organization, Trial of the century, Infection, Bill, Disease, Tuberculosis, Pharmaceutical industry

MONTREAL, March 28, 2024 /PRNewswire/ -- Canadian-based Noze, a global leader in the breath-based diagnostic space, announced today it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation's total grant funding to Noze to $1.8 million. The announcement comes on the heels of World Tuberculosis Day, which was recognized on March 24th.

Key Points: 
  • The announcement comes on the heels of World Tuberculosis Day, which was recognized on March 24th.
  • This new grant will support Noze's capacity to profoundly influence the management and eradication of infectious diseases," noted Karim Aly, CEO of Noze.
  • "The ability to perform high-yield, low cost screening of tuberculosis is a critical driver in ending the global epidemic.
  • With the second grant in place, Aly noted he expects the clinical study to begin in the fall of 2024.

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on: 
Monday, March 25, 2024
Knowledge, Control, Moxifloxacin, Health, TDF, Government, Disease, Tuberculosis, Partnership, Trustee, Research, Linezolid, DOH, Senior, World Health Organization, Directorate, WHO, TB, Market access, Interim, NTRL, Molina Healthcare, TB Alliance, Miliary tuberculosis, Pharmaceutical industry

MANILA, Australia, March 24, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points: 
  • The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
  • "PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
  • "Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
  • The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on: 
Monday, March 25, 2024
Knowledge, Control, Moxifloxacin, Health, TDF, Government, Disease, Tuberculosis, Partnership, Trustee, Research, Linezolid, DOH, Senior, World Health Organization, Directorate, WHO, TB, Market access, Interim, NTRL, Molina Healthcare, TB Alliance, Miliary tuberculosis, Pharmaceutical industry

MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points: 
  • The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
  • "PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
  • "Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
  • The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.